Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWK002 in refractory rheumatoid arthritis
NCT06503237Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2023
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SWK002 in rheumatoid arthritis (RA), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Safety Outcome up to 2 years. Started Nov 2023; status: recruiting.
02
Drugs
SWK002
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06503237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503237.